Primary Cutaneous CD4-Positive Small/Medium T-Cell Lymphoproliferative Disorder
NCI Definition: A primary cutaneous T-cell lymphoma. It usually presents with a solitary plaque or tumor on the face, neck, or upper trunk. Morphologically, it is composed of small to medium-sized CD4-positive, CD8-negative, and CD30-negative pleomorphic T-lymphocytes. A small number of large pleomorphic T-lymphocytes may also be present. The lymphocytic infiltrate is dermal. Focal epidermotropism and subcutaneous involvement may be present. The prognosis is favorable. 
Primary cutaneous CD4-positive small/medium T-cell lymphoproliferative disorders most frequently harbor alterations in SMARCA4 .
SMARCA4 R1093* and SMARCA4 Mutation are the most common alterations in primary cutaneous CD4-positive small/medium T-cell lymphoproliferative disorder .
There is 1 clinical trial for primary cutaneous CD4-positive small/medium T-cell lymphoproliferative disorder, of which 1 is open and 0 are completed or closed. Of the trial that contains primary cutaneous CD4-positive small/medium T-cell lymphoproliferative disorder as an inclusion criterion, 1 is phase 2 (1 open).
Azacitidine and romidepsin are the most common interventions in primary cutaneous CD4-positive small/medium T-cell lymphoproliferative disorder clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.